Halozyme ups guidance after Q2

Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.741 

Royalty Revenue Increased 31% YOY to Record $111.7 million

Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65-$2.75

Updated Revenue Guidance to $825-$845 million, Representing 25-28% YOY Growth, and EBITDA Guidance to $420-$440 million, Representing >30% YOY Growth1    

https://finance.yahoo.com/news/halozyme-reports-second-quarter-2023-200100712.html